• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    President and CEO Fraser Craig bought $4,942 worth of shares (5,431 units at $0.91), increasing direct ownership by 169% to 8,638 units (SEC Form 4)

    10/9/24 7:46:52 AM ET
    $WINT
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $WINT alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Fraser Craig

    (Last) (First) (Middle)
    C/O WINDTREE THERAPEUTICS, INC.
    2600 KELLY ROAD, SUITE 100

    (Street)
    WARRINGTON PA 18976

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    WINDTREE THERAPEUTICS INC /DE/ [ WINT ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    X Officer (give title below) Other (specify below)
    President and CEO
    3. Date of Earliest Transaction (Month/Day/Year)
    10/08/2024
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 10/08/2024 P 5,431 A $0.9099 8,638(1) D
    Common Stock 1(1)(2) I By Trust
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Adjusted to reflect 1-for-18 reverse stock split effective April 19, 2024.
    2. Holding amount represents issuer's matching stock contribution pursuant to 401(k) plan.
    /s/ Jamie McAndrew, as Attorney-in-Fact 10/09/2024
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $WINT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WINT

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $WINT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Oppenheimer initiated coverage on Windtree Therapeutics with a new price target

      Oppenheimer initiated coverage of Windtree Therapeutics with a rating of Outperform and set a new price target of $8.00

      6/4/21 6:09:49 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $WINT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Windtree Announces Publication of Istaroxime Positive Phase 2 SEISMiC B Study

      The Phase 2 Istaroxime study was successful in multiple endpoints showing promise for how it may be utilized if approved in its targeted indications    Primary endpoint of the study was met of increasing systolic blood pressure and demonstration of other benefits including no increase in heart rate and preserved renal function Partnership discussions with multiple potential partners that may fund the remainder of clinical development thus eliminating the Company's cash burn with the cardiovascular pipeline Phase 2 SEISMiC C interim data results targeted for July Final stages of protocol design for Phase 3 in acute heart failure indication for China nearly complete for regional

      6/16/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Receives Offer for Its Preclinical Oncology Drug Candidate

      Company to receive $7.0 million up front for its preclinical oncology drug candidate Up to $130.0 million in milestone payments starting with initiation of Phase 1 High single digit royalties that could total up to $1.5 billion over the life of the drug WARRINGTON, Pa., June 11, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, announced that it has received a non-binding letter of intent to purchase its preclinical oncology aPKCi inhibitor platform for $7.0 million dollars up front in cash or freely tradable stock and up to $130 million in milestone p

      6/11/25 9:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Windtree Announces Transformational Agreement to Acquire Revenue Generating Environmental Services Business

      Windtree continues its transformation entering the rapidly growing $85 billion US environmental services space Refocused strategy is expected to generate $12 million in revenue over the next 12 months Transaction expected to produce a profitable business with growth opportunities through a roll up strategy Windtree continues to pursue partnership or sale of pharmaceutical assets to reduce costs WARRINGTON, Pa., June 10, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a diversified company focused on revenue generation in multiple growing industries, today announced a significant step in its drive toward overall profitability through

      6/10/25 8:00:00 AM ET
      $WINT
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care